Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS

(NOVN)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis : Greek Parliament to Vote on Prosecutions in Novartis Bribery Case

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/18/2018 | 08:17am EST

By Nektaria Stamouli and Donato Paolo Mancini

ATHENS--Greece's Parliament is set to vote later on Friday on whether or not to request the prosecution of high-profile politicians allegedly involved in a bribery case with Swiss pharmaceutical giant Novartis.

Parliament is expected to conclude it cannot investigate the allegations and that the file should be returned to judicial authorities.

In Greece, Novartis is accused of bribing high-profile politicians, public officials and thousands of doctors to boost its sales in order to build a dominant position in the country's health-care market and secure artificially high prices for its products. The case is under examination by the Greek and U.S. authorities.

Greek anticorruption prosecutors alleged that 4,500 doctors and 10 high profile politicians, including two former prime ministers, a former head of the central bank and a European commissioner are involved in the Novartis price-fixing scandal.

The activity occurred between 2006 and 2015 and involved 4,500 doctors as well, covering the period during which Greece was bailed out and was living under tight scrutiny by its international creditors. The country has slashed health-care spending to fix its finances.

All politicians denied wrongdoing. Opposition parties accused the government of stoking the scandal for political gain. Novartis has said that it has been cooperating with Greek authorities and that it will take "decisive" action if any wrongdoing is found.

The case was referred to parliament by prosecutors in February because, under Greek law, this is the only institution that can investigate politicians and lift their immunity if it finds evidence of criminal activity. Prosecutors referred their investigation to parliament this month.

Novartis is under pressure after drawing the attention of Swiss prosecutors after disclosing last week that it had paid a total of $1.2 million to Essential Consultants LLC, a company owned by Michael Cohen. Mr. Cohen is U.S. President Donald Trump's personal attorney.

Novartis said the payments were for what it called advice on "health-care policy matters."

Novartis's chief executive Vasant Narasimhan called the move a mistake. The company said payments could only cease in February 2018 even if the company had been determined Mr. Cohen was unable to effectively offer advice on health-care policy, and that Mr. Narasimhan was not involved in the deal with Mr. Cohen. Mr. Cohen declined to comment.

In the wake of the disclosures, Novartis's top lawyer, Felix Ehrat, said he would leave the company. Mr. Narasimhan said Wednesday at an investor meeting in Basel that changes in top management would be made, and that a new professional-practices policy would be in place so employees could "ask themselves the key questions before making a decision."

Swiss prosecutors said earlier this week they were in contact with one another over the disclosures, but declined to say whether charges were being considered.

Read more about Novartis's connection to Michael Cohen at https://on.wsj.com/2k61xoQ (WSJ) or https://bit.ly/2IN3Bjl (NewsPlus).

Write to Nektaria Stamouli at nektaria.stamouli@wsj.com and to Donato Paolo Mancini at donatopaolo.mancini@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
02/13NOVARTIS : receives FDA approval for Egaten® for the treatment of fascioliasis, ..
GL
02/13CLINIGEN : agrees to buy U.S. rights to Novartis' cancer drug Proleukin
RE
02/11RECRO PHARMA : in New Supply Agreement with Novartis
DJ
02/07GLOBAL MARKETS LIVE : General Motors, Sonos, Chipotle Mexican Grill, Publicis ....
02/07NOVARTIS : CEO lauds Trump administration plan to overhaul rebates
RE
02/06NOVARTIS INDIA : Q3 profit dips 31% to Rs 13 crore
AQ
02/05NOVARTIS : Alcon eye-care unit to enter Swiss index after spin off
RE
02/05Merck KGaA, GSK Enter Immuno-Oncology Deal Worth Up to $4.23 Billion -- Updat..
DJ
02/04SURFACE ONCOLOGY : Keeps Worldwide Rights to SRF388 After Novartis Passes on Opt..
DJ
02/04Biopharmaceutical Market to Reach USD 218483.0 Million by 2023 Growing at a C..
AQ
More news
Financials ($)
Sales 2019 53 517 M
EBIT 2019 14 117 M
Net income 2019 8 856 M
Debt 2019 14 672 M
Yield 2019 3,32%
P/E ratio 2019 22,10
P/E ratio 2020 19,81
EV / Sales 2019 4,55x
EV / Sales 2020 4,27x
Capitalization 229 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 94,4 $
Spread / Average Target 5,3%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant T. Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS7.19%228 685
JOHNSON & JOHNSON4.08%365 768
PFIZER-3.85%245 920
ROCHE HOLDING LTD.11.98%233 242
MERCK AND COMPANY4.45%207 536
ELI LILLY AND COMPANY4.35%129 746